RFG Advisory LLC Acquires 366 Shares of IDEXX Laboratories, Inc. $IDXX

RFG Advisory LLC grew its holdings in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 5.7% during the second quarter, HoldingsChannel reports. The institutional investor owned 6,776 shares of the company’s stock after buying an additional 366 shares during the period. RFG Advisory LLC’s holdings in IDEXX Laboratories were worth $3,634,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of IDXX. Price T Rowe Associates Inc. MD grew its stake in shares of IDEXX Laboratories by 71.0% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,988,912 shares of the company’s stock valued at $835,244,000 after buying an additional 825,965 shares during the last quarter. Select Equity Group L.P. purchased a new stake in shares of IDEXX Laboratories in the first quarter valued at approximately $194,834,000. Nuveen LLC purchased a new stake in shares of IDEXX Laboratories in the first quarter valued at approximately $179,784,000. Principal Financial Group Inc. boosted its holdings in shares of IDEXX Laboratories by 58.3% in the first quarter. Principal Financial Group Inc. now owns 1,126,002 shares of the company’s stock valued at $472,865,000 after purchasing an additional 414,802 shares during the period. Finally, Durable Capital Partners LP purchased a new stake in shares of IDEXX Laboratories in the first quarter valued at approximately $153,180,000. Institutional investors own 87.84% of the company’s stock.

Insider Activity

In other news, Director M Anne Szostak sold 2,187 shares of the stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the sale, the director owned 262 shares in the company, valued at approximately $169,600.46. This represents a 89.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Nimrata Hunt sold 1,200 shares of the stock in a transaction on Monday, August 11th. The shares were sold at an average price of $656.53, for a total value of $787,836.00. Following the sale, the executive vice president owned 16,807 shares of the company’s stock, valued at approximately $11,034,299.71. This represents a 6.66% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 54,057 shares of company stock worth $34,293,468. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Stock Up 0.6%

IDEXX Laboratories stock opened at $636.91 on Wednesday. The business has a fifty day moving average of $640.40 and a two-hundred day moving average of $545.72. The company has a quick ratio of 0.79, a current ratio of 1.11 and a debt-to-equity ratio of 0.31. The firm has a market cap of $50.96 billion, a P/E ratio of 53.03, a P/E/G ratio of 4.10 and a beta of 1.58. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $688.12.

IDEXX Laboratories (NASDAQ:IDXX) last posted its earnings results on Monday, August 4th. The company reported $3.63 earnings per share for the quarter, topping analysts’ consensus estimates of $3.28 by $0.35. The company had revenue of $1.11 billion during the quarter, compared to analyst estimates of $1.06 billion. IDEXX Laboratories had a return on equity of 64.42% and a net margin of 24.41%.IDEXX Laboratories’s revenue was up 10.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. On average, analysts forecast that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IDXX has been the subject of a number of research reports. BTIG Research boosted their price target on IDEXX Laboratories from $545.00 to $785.00 and gave the company a “buy” rating in a report on Tuesday, August 5th. Leerink Partners boosted their price target on IDEXX Laboratories from $580.00 to $600.00 and gave the company an “outperform” rating in a report on Thursday, July 17th. Morgan Stanley boosted their price target on IDEXX Laboratories from $722.00 to $765.00 and gave the company an “overweight” rating in a report on Friday, August 15th. JPMorgan Chase & Co. boosted their price target on IDEXX Laboratories from $550.00 to $675.00 and gave the company an “overweight” rating in a report on Monday, August 4th. Finally, Stifel Nicolaus set a $640.00 price target on IDEXX Laboratories in a report on Monday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $656.50.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.